AKT1 and AKT2 KO Cells

Case ID:
C10770

C10770: AKT1 and AKT2 KO Cells

Value Proposition:

Cell Lines

AKT1-/- (D3A8G5) in HCT116
AKT1-/- (H1D1A12) in HCT116
AKT1-/-, AKT2-/- (HDK1-B2-F12-E5) in HCT116
AKT1-/-, AKT2-/- (HDK2-E1-B2-G3) in HCT116
AKT2-/- (A10A5C6) HCT116 in HCT116
AKT2-/- (C12B8B5) HCT116 in HCT116
AKT1-/- (D6D7A12) in DLD1
AKT1-/- (G10C3C5) in DLD1
AKT1-/-, AKT2-/- (DDK3-C2-G4-H2) in DLD1
AKT1-/-, AKT2-/- (DDK4-E11-A3-A8) in DLD1

Technical Details:

JHU scientists have developed several AKT knockouts in human colorectal cancer cell lines HCT116 and DLD1. The AKT protein family, consisting of Akt1, Akt2, and Akt3, plays an important role in mammalian cellular signaling. Members of the family are also called protein kinases B (PKB).

Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes. Since Akt1 can block apoptosis, and thereby promote cell survival, it has been implicated as a major factor in many types of cancer.
Akt2 is an important signaling molecule in the Insulin signaling pathway but has also been associated with a malignant phenotype of a subset of human colorectal cancers.

Looking for Partners:

The cell lines described can be used in screens for novel molecules that target the Akt pathway in human cancer cells to confirm the specificity of drugs discovered through other approaches. Such drugs can potentially be used as chemotherapeutic or chemopreventive agents.



Patent Information:
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum